Epigallocatechin-3-gallate (EGCG) Regulates Anti-Inflammatory Action : Improving Intestinal Permeability and Changing in Gut Microbiota
學生姓名:
蔡宜家
指導教授:
吳彰哲
學期:
111上
摘 要:
There are approximately 1.2 million people diagnosed with colorectal cancer (coloncancer) every year, and it is the third most common cancer in the human population. There is a fairly high incidence of colon cancer in developed countries. The humanbody contains about 1000 kinds of bacteria, approximately 1014 in total, most of which are distributed in the large intestine. The biological availability of epigallocatechin gallate (EGCG) is low, most EGCG is fermented by bacteria in the large intestine, and discharged with stool. The large intestine is the main metabolic site for EGCG and is also the most active portion of the body for the interaction with bacteria. Importantly, when compared to smaller bacteria density in the proximal small intestine, the incidence of colorectal cancer is significantly higher. Therefore, the interaction of EGCG with gut microbiota is very likely to affect the occurrence and development of colorectal cancer. Combining the above results, EGCG has the underlying mechanism of action to the suppress of colorectal carcinogenesis.
11032038摘要.pdf